PM 1268
Alternative Names: PM-1268Latest Information Update: 05 Feb 2024
At a glance
- Originator Biotheus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Interleukin 31 receptor antagonists; Interleukin 4 receptor alpha subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Dec 2023 Preclinical trials in Cancer in China (unspecified route), prior to December 2023 (Biotheus pipeline, December 2023)